XOMA (XOMA)
(Delayed Data from NSDQ)
$25.28 USD
-1.42 (-5.32%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $25.56 +0.28 (1.11%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Brokerage Reports
XOMA Corporation [XOMA]
Reports for Purchase
Showing records 21 - 40 ( 330 total )
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
1Q22 Results; All RIZE for Positive Phase 2b Readout in CHI from Partnered Asset
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
All RIZE for Positive Phase 2b Readout in CHI from XOMA Partnered Asset
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
RZ358 Continues to Advance; Positive Clinical Update From Partnered Asset With Data Presentation Expected 1H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
2021 Results; Assets Picking Up Steam With Rapidly Maturing Portfolio; First Royalty Check Soon
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
It Begins; First Approved Royalty Stream Coming; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Wake Up and Get a $35M Check; 3Q21 Results Continue to Show Partners'' Progress
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Emerging Pharmaceuticals - Dropping Coverage
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Nice New Clarity and a Likely Accelerated Revenue Stream; Price Target Increased to $69
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Iscalimab Discontinued in Kidney Transplantation; Downgrading to NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Q2 Update: With Padded Balance Sheet, Looking to Add to 70+ Partnered Portfolio
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
2Q21 Results; Strong Financials Bolstered by Growing and Maturing Portfolio; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Double the Good News; Positive Regulatory Updates From Two Partners
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Portfolio Continues to Expand With Checkmate Asset Acquisition
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Q1 Update: Partnered Assets Now at 70+ with Additional Cash to Acquire More
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
1Q21 Results; Multi-Year Cash Runway for Continued Shopping as Partners Continue to Advance
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
As Royalty Portfolio Visibility Improves, Depth of Asset Pipeline Impresses
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J